Literature DB >> 26082811

Changes in Skeletal Tumor Activity on (18)F-choline PET/CT in Patients Receiving (223)Radium Radionuclide Therapy for Metastatic Prostate Cancer.

Kyle S Miyazaki1, Yu Kuang2, Sandi A Kwee3.   

Abstract

Radium-223 dichloride is an alpha-emitting radiopharmaceutical shown to prolong survival in patients with castrate-resistant prostate cancer (CRPC) and symptomatic skeletal metastases. This report describes in two patients the acute changes in bone metastatic activity detected by F-18 choline PET/CT imaging midway during treatment with radium-223 dichloride. In addition to visual and standardized uptake value analysis, changes in the whole-body tumor burden were quantified by measuring the difference in net metabolically active tumor volume (MATV) and total lesion activity (TLA) between pre- and mid-treatment PET scans. After the third dose of radium-223 dichloride, near-total disappearance of abnormal skeletal activity was observed in one case (net MATV change from 260.7 to 0.8 cc; net TLA change from 510.7 to 2.1), while a heterogeneous tumor response was observed in the other (net MATV change from 272.2 to 241.3 cc; net TLA change from 987.1 to 779.4). Corresponding normalization and persistent elevation in serum alkaline phosphatase levels were observed in these cases, respectively. Further research is needed to determine the predictive value of serial F-18 choline PET/CT imaging in patients receiving radium-223 dichloride for CRPC.

Entities:  

Keywords:  Castrate-resistant prostate cancer; Fluorocholine; PET/CT; Radium-223 dichloride

Year:  2015        PMID： 26082811      PMCID： PMC4463874          DOI： 10.1007/s13139-014-0314-0

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN： 1869-3474


  8 in total

1.  2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy.

Authors:  Heiko Schöder; Ken Herrmann; Mithat Gönen; Hedvig Hricak; Stephen Eberhard; Peter Scardino; Howard I Scher; Steven M Larson
Journal:  Clin Cancer Res       Date:  2005-07-01       Impact factor: 12.531

Review 2.  Choline metabolism in cancer: implications for diagnosis and therapy.

Authors:  Kristine Glunde; Michael A Jacobs; Zaver M Bhujwalla
Journal:  Expert Rev Mol Diagn       Date:  2006-11       Impact factor: 5.225

3.  Prognosis Related to Metastatic Burden Measured by ¹⁸F-Fluorocholine PET/CT in Castration-Resistant Prostate Cancer.

Authors:  Sandi A Kwee; John Lim; Alex Watanabe; Kathleen Kromer-Baker; Marc N Coel
Journal:  J Nucl Med       Date:  2014-03-27       Impact factor: 10.057

4.  Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy.

Authors:  Guru Sonpavde; Gregory R Pond; William R Berry; Ronald de Wit; Andrew J Armstrong; Mario A Eisenberger; Ian F Tannock
Journal:  Urol Oncol       Date:  2010-10-02       Impact factor: 3.498

5.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

6.  Effect of erythropoietin on bone marrow uptake of 18F-fluorocholine in prostate cancer: comparison with 18F-fluoride uptake.

Authors:  Sona Balogova; Virginie Huchet; Christoph Egrot; Laure Michaud; F Paycha; Khaldoun Kerrou; Francoise Montravers; Olivier Cussenot; Jean Noel Talbot
Journal:  Clin Nucl Med       Date:  2013-03       Impact factor: 7.794

7.  Alpha emitter radium-223 and survival in metastatic prostate cancer.

Authors:  C Parker; S Nilsson; D Heinrich; S I Helle; J M O'Sullivan; S D Fosså; A Chodacki; P Wiechno; J Logue; M Seke; A Widmark; D C Johannessen; P Hoskin; D Bottomley; N D James; A Solberg; I Syndikus; J Kliment; S Wedel; S Boehmer; M Dall'Oglio; L Franzén; R Coleman; N J Vogelzang; C G O'Bryan-Tear; K Staudacher; J Garcia-Vargas; M Shan; Ø S Bruland; O Sartor
Journal:  N Engl J Med       Date:  2013-07-18       Impact factor: 91.245

8.  Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer.

Authors:  David T Price; R Edward Coleman; Ray P Liao; Cary N Robertson; Thomas J Polascik; Timothy R DeGrado
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450
  8 in total
  13 in total

1.  Prediction of PSA Progression in Castration-Resistant Prostate Cancer Based on Treatment-Associated Change in Tumor Burden Quantified by 18F-Fluorocholine PET/CT.

Authors:  Joohee Lee; Miles M Sato; Marc N Coel; Kyung-Han Lee; Sandi A Kwee
Journal:  J Nucl Med       Date:  2016-02-16       Impact factor: 10.057

Review 2.  Therapy assessment of bone metastatic disease in the era of 223radium.

Authors:  Elba Etchebehere; Ana Emilia Brito; Alireza Rezaee; Werner Langsteger; Mohsen Beheshti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-31       Impact factor: 9.236

Review 3.  18F-NaF/223RaCl2 theranostics in metastatic prostate cancer: treatment response assessment and prediction of outcome.

Authors:  Hossein Jadvar; Patrick M Colletti
Journal:  Br J Radiol       Date:  2018-04-16       Impact factor: 3.039

Review 4.  Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223.

Authors:  A Rodriguez-Vida; M D Torregrosa; Á Pinto; M Á Climent; D Olmos; J Carles
Journal:  Clin Transl Oncol       Date:  2017-11-02       Impact factor: 3.405

Review 5.  Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer.

Authors:  Hossein Jadvar
Journal:  Abdom Radiol (NY)       Date:  2016-05

Review 6.  Radium-223 dichloride in clinical practice: a review.

Authors:  Luigia Florimonte; Luca Dellavedova; Lorenzo Stefano Maffioli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-28       Impact factor: 9.236

Review 7.  Radium-223 and metastatic castration-resistant prostate cancer: All that glitters is not gold.

Authors:  Carlo Aprile; Marco G Persico; Lorenzo Lodola; Federica E Buroni
Journal:  World J Radiol       Date:  2016-10-28

Review 8.  Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiology.

Authors:  Gary J R Cook; Gurdip Azad; Anwar R Padhani
Journal:  Clin Transl Imaging       Date:  2016-07-20

9.  Combined bone scintigraphy and fluorocholine PET/computed tomography predicts response to radium-223 therapy in patients with prostate cancer.

Authors:  Michele Klain; Valeria Gaudieri; Mario Petretta; Emilia Zampella; Giovanni Storto; Carmela Nappi; Carlo Buonerba; Felice Crocetto; Rosj Gallicchio; Fabio Volpe; Leonardo Pace; Martin Schlumberger; Alberto Cuocolo
Journal:  Future Sci OA       Date:  2021-05-21

Review 10.  Positron Emission Tomography Imaging of Tumor Cell Metabolism and Application to Therapy Response Monitoring.

Authors:  Amarnath Challapalli; Eric O Aboagye
Journal:  Front Oncol       Date:  2016-02-29       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.